Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/ Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Funda Meric-Bernstam*, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc PelletierShahneen Sandhu

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/ Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science